Affinia Therapeutics
CompanyUnited States
Affinia Therapeutics develops one asset, in phase 1 (AFTX-201 in BAG3 mutation associated dilated cardiomyopathy). Mostly gene therapy; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- $40M
- 1
- Trial
- 1
- Signal
Pipeline
1Delivers a functional BAG3 gene to restore BAG3 protein expression in heart muscle cells.
Phase 1, Gene therapy, BAG3 mutation associated dilated cardiomyopathy, dilated cardiomyopathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants1
- Signals3
- Similar companies6